SCLX Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio—Forward 2.66
EPS (TTM)$-36.480.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$74.4MMicro cap
Valuation
- Forward P/E
- 2.66
- PEG ratio
- —
- P/B
- 28.85
- P/S (TTM)
- 2.46
- EV/EBITDA
- -2.64
Profitability & growth
- ROE (TTM)
- 0.0%
- Operating margin
- -782.0%
- Revenue growth YoY
- -67.8%
- Dividend yield
- —
- Beta
- 1.42
Last earnings
Feb 25, 2026 · Estimate $-0.47 · Reported $-1.17
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Scilex Holding Company
Company profileScilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company is headquartered in Palo Alto, California.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 960 SAN ANTONIO ROAD, PALO ALTO, CA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$74.4M
Shares outstanding$7.0M
52W high$34.27
52W low$3.92
Educational content · Not investment advice or recommendations
We're educators, not advisors. Your decisions are your own. Disclaimer
B
Agent
The AI built for clarity
I'm your AI thinking companion for the markets — I can help you explore and learn, but I'm not a financial advisor. Everything here is educational. Disclaimer
B
Agent